



ADVANCED WOUND CARE SUMMIT

PRESENTS

SHOWCASE 20
FINALISTS 23

We're thrilled to present the 6 brands that have been shortlisted for the Innovation Showcase.

This is the first industry-led forum focused on delivering innovative wound care treatments to patients.

**Kisaco
Research**

ABOUT

Acteev®

At its core, Acteev MED incorporates the antimicrobial benefits of active zinc ions straight into superior polyamide, a material of choice in high-stakes applications: sutures, wound care, medical packaging and devices. Unlike other antimicrobial treatments, Acteev's zinc ions are embedded into the product instead of coated on. Even after 50 washes, it's still as effective as day one. Acteev MED is the answer to a world demanding products that are clean, safe and durable. We work with customers to drive innovation, from trusted consumer applications to new healthcare technologies.



www.acteev.com

Dr. Rajib Mondal
Principal Scientist
Ascend Performance
Materials



Dr. Rajib Mondal is a Principal Scientist at Ascend Performance Materials, specializing in wound care innovation. With over 12 years of industrial experience, he is an expert in developing advanced skin, wound, and burn care products using nylon technology. Dr. Mondal holds a Ph.D. in Chemistry from Bowling Green State University and completed his post-doctoral fellowship at Stanford University. He has authored 30+ peer-reviewed papers and holds 12 patents, showcasing his expertise in the field.

Kimberly Grace
Senior Business Development
Leader
Acteev



Kimberly Grace is a Senior Business Development Leader at Acteev MED, specializing in the field of wound care and currently partnering with renowned healthcare companies to innovate on their existing wound care applications. With over 18 years of experience in the medical device industry, she has a stellar track record of leading sales effectiveness programs and launching advanced wound care products in the industry.

ABOUT



In 2005, Adtec was the first company worldwide to introduce the treatment of cold plasma on chronic wounds for medical use in clinical trials, much of which is still widely discussed today for having paved way for other plasma enthusiasts to broaden their cold plasma studies. Much of what you see today begun from the start of our first clinical trials over a decade ago using our first medical device, the Adtec MicroPlaSter. The results have proved the antibacterial efficacy and accelerated wound healing advantage that our patented plasma technology has over treating patients alone with standard antimicrobial therapies.

Mary McGovern
Managing Director
Adtec Healthcare



Experienced Managing Director in UK and Director of Japanese company with a demonstrated history of working in the semiconductor and medical device manufacturing industries. Founder of Adtec Healthcare. Skilled in Sales, Disruptive Innovation , business development in new markets & new regions , Customer Relationship Management (CRM), Strategic Partnerships, International Sales, and Management.



ABOUT



HidraWear offers completely adhesive free, secure dressing fixation and retention, and is clinically proven to reduce pain and improve quality of life.

Suzanne Moloney
CEO & Founder
HidraWear



From Patient to Provider - I have lived with debilitating chronic wounds since my teenage years, and developed HidraWear Wearable Wound Care, as a solution to my own wound care challenges, and for the millions of patients globally with wounds in difficult to dress locations such as the axilla, groin and buttocks.



www.hidrawear.com

ABOUT

Lextro^o Labs

Lextro Labs was established in the year 2022, at Genome Valley, a vibrant biotech cluster in the city of Hyderabad, India by Mr. Srinivas Akkina, as a Co-founder & Managing Director. Lextro Labs is a discovery stage biopharmaceutical company engaged in the development of first-in-class and best-in-class biotherapeutics through “Immune modulation and Cytotoxicity, (ImCy) a platform technology”. ImCy restores underlying homeostatic mechanisms such that long lasting responses are attained in indications such as Cancer, Autoimmune, Metabolic and Infectious diseases. By focusing on immune modulation and cytotoxicity, we seek to address the root causes of diseases and provide effective solutions for patients worldwide.

Murali Addepalli
Co-founder & CSO
Lextro Labs



Murali Addepalli is a Co-founder & CSO of Lextro Labs having 21+ years of experience in the field of Drug Discovery & Development. After obtaining his PhD from Nagasaki University (Japan), he gained valuable experience at NIH, Bethesda (USA) as a Post-doctoral Fellow. He has a proven track record of creating therapeutic pipelines and generating a significant Intellectual Properties. Dr. Murali has been associated with 17+ discovery programs in various capacities spanning across immuno-oncology, metabolic disorders, autoimmune and infectious diseases. Some of these molecules are in advanced stages of clinical development. He has published 25+ research articles in prestigious journals.



ABOUT

Nanordica Medical

Nanordica Medical is a pioneer in antimicrobial nanotechnology. We developed a combination of nanoparticles that have synergistic antibacterial effects and therefore, remove infection 8x better compared to traditional silver ion-based solutions. This enables to reduce inflammation and improve wound healing, leading to the healing of chronic wounds that cannot be cured with other methods according to pilot clinical trial. Our solution uses 10x less silver and has fewer adverse effects in patients compared to the common silver-based solutions. We will be happy to discuss potential collaborative projects with wound care companies looking for superior antibacterial technologies and meet medtech investors.



www.nanordica.com

Olesja Bondarenko
CEO & Co-founder
Nanordica



Olesja Bondarenko received PhD degree in gene technology from Tallinn University of Technology (Estonia) in 2012, practiced at the University of Konstanz (Germany) and was a postdoctoral researcher at Karolinska Institutet (Sweden) and the University of Helsinki (Finland). Her research focused on the biological effects and safety of nanoparticles. Dr. Bondarenko is one of the pioneers in the nanoparticle research field with more than 30 peer-reviewed articles, highly cited publications, and numerous highly competitive EU grants and awards.

Since 2019, she is a co-founder and CEO of Nanordica Medical developing advanced nanoparticle-based antibacterial solutions with a focus on wound care.

ABOUT



Six Therapeutics is developing a DNA platform therapeutic. This technology is backed by decades of research and validated by the NIH. The initial indication is for the treatment of Acute Radiation Dermatitis (ARD), a common side effect of radiation therapy in cancer patients for which there is no approved therapeutic and current options are poor. ARD causes major wounds to develop which lead to infections and treatment interruptions creating significant patient risks and increased healthcare costs. Initial data generated by Six Therapeutics demonstrate accelerated healing and a promising safety profile building conviction in this technology.

Nyron Khan
Co-founder
Six Therapeutics



Nyron Khan is a proven executive in the pharma/biotech industry with a successful, 30-year track record leading commercial teams. Nyron has worked across all major therapeutic areas where he has built teams and led launches of several billion-dollar pharmaceutical brands. He is especially driven by building and advancing companies with innovative technologies. He is the co-founder of Six Therapeutics Inc., a preclinical stage biotech company and serves as advisor to several other emerging start-up organizations. Nyron is a passionate leader and collaborator always willing to lend his skills and experience to nurture the next generation of leaders.

ABOUT



SUN SCIENTIFIC

Founded by vascular surgeon, Dr. Ravikumar, Sun Scientific is a solutions-focused medical device company leading the way in patient-centric treatments for chronic, prevalent, and growing diseases. Sun Scientific's AeroCare™ System is a paradigm shift in Venous Leg Ulcer (VLU) treatment – simplifying, standardizing, and improving the 3 essential elements of successful wound care: Wound Dressing, Exudate Management, and Compression Therapy – with a product suite developed for improved clinical care and patient self-management.

Vikram Ravikumar
Chief Operating Officer
Sun Scientific



Vikram leads day-to-day operations of Sun Scientific, having been involved in the product design and development of its compression and wound care products from their inception. Since 2009, he has been working alongside a serial inventor surgeon founder and R&D team, leading commercialization strategy and execution of IP in multiple clinical segments including at Mini-Lap Technologies. Mini-Lap pioneered percutaneous laparoscopic instrumentation and its instruments were distributed by Stryker from 2009 until it was acquired by Teleflex in 2014.



www.sun-scientific.com

ABOUT



Suramedical is a seed-stage startup co-founded by a wound care provider. Suramedical is innovating a wearable - WoundAlert - designed for patients suffering from venous leg ulcerations. WoundAlert is small and inexpensive and placed within the layers of the compression bandage away from the wound by the wound care provider at the time of dressing changes. WoundAlert noninvasively monitors patient activity and leg elevation and provides the patient with feedback regarding their daily behavior via a smartphone application. WoundAlert also monitors for loosening of the compression bandage. Suramedical is funded by an award from the NIH SBIR Phase 1 program.

Noah A. Rosen, MD,
MBA
CMO / Cofounder
Suramedical



Noah Rosen MD, MBA is a Board-certified Vascular Surgeon and a Boston Magazine/Castle Connolly Top Doctor since 2016. Dr. Rosen has treated hundreds of patients suffering from leg wounds over the past 20 years, bearing witness to the failures of the delivery of the standard of care. Dr. Rosen is also an inventor and entrepreneur, having earned an executive MBA from Brandeis University in 2022. Dr. Rosen graduated from MIT with a Bachelor's of Science degree in Electrical Engineering; during his time in Cambridge, he was a member of the renowned MIT blackjack team



www.suramedical.com

ABOUT



UNTECH

Untech is a Drug development company focused on chronic wounds that have developed a breakthrough proprietary medication (45 countries) that includes all recommended therapeutic requirements in a single product. Prestigious institutions like Stanford University, MIT, Samsung, and Born2Global in South Korea awarded the company. It was also chosen as a great promise by Forbes Magazine and an Independent report from StartUs Insights based on AI named Untech as One of the Top 5 Wound Care Management Startups in the world.

Dr. Alberto Ramos
Vernieri
CSO & co-founder
Untech



He has a degree in chemistry and biochemistry, a Ph.D. in biochemistry, and postdoctoral studies in Pharmaceutical biotechnology and immunology. For 15 years, he led various types of research regarding chronic wounds and has won several awards at international congresses, publishing several papers and books on the matter. He is the principal inventor of this technology for which he was awarded the Ten Outstanding Young Person (Junior Chamber International). In academia, he was a Professor in the Immunology Chair, a CONICET researcher, and co-founder and Director of the Laboratory of Pharmaceutical Biotechnology (CONICET-UNT).



www.unttech.bio

ABOUT

Vaporox

with VHT™

The New Standard in Wound Care

Vaporox is a Denver-based medical device company commercializing Vaporous Hyperoxia Therapy (VHT), a patented and FDA 510(k)-cleared technology that has been clinically validated as a safe and effective treatment for healing wounds. Vaporox's initial focus is on diabetic foot ulcers (DFUs). About 30 million Americans have diabetes and this population suffers from over 2 million DFUs, with about 550,000 new cases diagnosed each year. Most DFUs (55% to 70%) do not heal with currently available treatments. VHT has been shown in multiple clinical studies and thousands of commercial treatments to heal 70-85% of the DFUs that resist standard treatment (i.e., chronic wounds).

Alan Sage
CEO/President
Vaporox



My career has largely been in startup ventures. I have led and built sales at a start-up from zero to \$25 million/year and managed over a hundred million in enterprise product sales in my career. I have also led and built a company from concept to market leadership and “Series B” VC investment. I have contributed to successful exits, via both IPO and acquisition. I frequently work with other entrepreneurs and executives to help them grow their ideas and organizations.



www.vaporox.com